Literature DB >> 17985686

Statin use in Canadians: trends, determinants and persistence.

C Ineke Neutel1, Howard Morrison, Norm R C Campbell, Margaret de Groh.   

Abstract

BACKGROUND: Regular statin use is an important tool in chronic disease management, lowering cholesterol levels and reducing risk of cardiovascular disease (CVD). The objectives of this study are to describe statin use in Canada by comorbidity and lifestyle risk factors, and determine persistence in statin use.
METHODS: The longitudinal National Population Health Survey, 1994-2002, is a random sample of the 1994 Canadian population and five interviews were conducted at two-year intervals. A total of 8,198 respondents, aged 20 in 1994, completed all five interviews. Information collected included demographic variables, medication use, CVD lifestyle risk factors, CVD, diabetes and hypertension.
RESULTS: Age-adjusted rates of statin use increased from 1.6% to 7.8% over the period 1994-2002. Statin use was higher with increasing age, diabetes, BMI, physician visits, and insurance for prescription medication. Although persons with CVD were more likely to take statins than those without, by 2002 still only 32.7% of heart patients were taking statins. Statin use did not increase linearly with increasing numbers of CVD risk factors or comorbidities. Of the 441 persons reporting statin use in 2000, 74.6% were still taking them in 2002. People who completed their high school education were more likely to continue taking statins than those who did not complete high school.
CONCLUSION: While statin use increased over time, was associated with CVD and diabetes, and to a lesser extent with increased BMI, a substantive underuse in high-risk patients remains. Helping high-risk people to increase statin use continues to be a priority for health care professionals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17985686      PMCID: PMC6976171     

Source DB:  PubMed          Journal:  Can J Public Health        ISSN: 0008-4263


  38 in total

1.  Recommendations for the management and treatment of dyslipidemia. Report of the Working Group on Hypercholesterolemia and Other Dyslipidemias.

Authors:  J G Fodor; J J Frohlich; J J Genest; P R McPherson
Journal:  CMAJ       Date:  2000-05-16       Impact factor: 8.262

2.  Coding of drugs used by respondents of the Canadian Study of Health and Aging.

Authors:  W Walop; M Semenchuk
Journal:  Can J Clin Pharmacol       Date:  2002

3.  Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update.

Authors:  Jacques Genest; Jiri Frohlich; George Fodor; Ruth McPherson
Journal:  CMAJ       Date:  2003-10-28       Impact factor: 8.262

4.  The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.

Authors:  Douglas G Manuel; Peter Tanuseputro; Cameron A Mustard; Susan E Schultz; Geoffrey M Anderson; Sten Ardal; David A Alter; Andreas Laupacis
Journal:  CMAJ       Date:  2005-04-12       Impact factor: 8.262

5.  Persistence and determinants of statin therapy among middle-aged patients free of cardiovascular disease.

Authors:  Sylvie Perreault; Lucie Blais; Alice Dragomir; Marie-Hèlène Bouchard; Lyne Lalonde; Claudine Laurier; Johanne Collin
Journal:  Eur J Clin Pharmacol       Date:  2005-10-19       Impact factor: 2.953

6.  Statin therapy in Canadian patients with hypercholesterolemia: the Canadian Lipid Study -- Observational (CALIPSO).

Authors:  C Bourgault; Jean Davignon; George Fodor; Claude Gagné; Daniel Gaudet; Jacques Genest; Marc-Andre Lavoie; Lawrence Leiter; Ruth McPherson; Martin Sénécal; Michael Marentette; Rolf J Sebaldt
Journal:  Can J Cardiol       Date:  2005-11       Impact factor: 5.223

7.  Lipid screening to prevent coronary artery disease: a quantitative evaluation of evolving guidelines.

Authors:  S A Grover; M Dorais; G Paradis; J G Fodor; J J Frohlich; R McPherson; L Coupal; H Zowall
Journal:  CMAJ       Date:  2000-11-14       Impact factor: 8.262

8.  Awareness, treatment, and control of hypertension in Canada.

Authors:  M R Joffres; P Ghadirian; J G Fodor; A Petrasovits; A Chockalingam; P Hamet
Journal:  Am J Hypertens       Date:  1997-10       Impact factor: 2.689

9.  Persistence with lipid-lowering therapy: influence of the type of lipid-lowering agent and drug benefit plan option in elderly patients.

Authors:  Susan M Abughosh; Stephen J Kogut; Susan E Andrade; Paul Larrat; Jerry H Gurwitz
Journal:  J Manag Care Pharm       Date:  2004 Sep-Oct

10.  National trends in statin use by coronary heart disease risk category.

Authors:  Jun Ma; Niraj L Sehgal; John Z Ayanian; Randall S Stafford
Journal:  PLoS Med       Date:  2005-05-31       Impact factor: 11.069

View more
  17 in total

1.  Statin use and risk of multiple myeloma: An analysis from the cancer research network.

Authors:  Mara M Epstein; George Divine; Chun R Chao; Karen E Wells; Heather Spencer Feigelson; Delia Scholes; Douglas Roblin; Marianne Ulcickas Yood; Lawrence S Engel; Andrew Taylor; Joan Fortuny; Laurel A Habel; Christine C Johnson
Journal:  Int J Cancer       Date:  2017-05-15       Impact factor: 7.396

Review 2.  Hypertension in people with type 2 diabetes: Update on pharmacologic management.

Authors:  Norm R C Campbell; Richard E Gilbert; Lawrence A Leiter; Pierre Larochelle; Sheldon Tobe; Arun Chockalingam; Richard Ward; Dorothy Morris; Ross T Tsuyuki; Stewart B Harris
Journal:  Can Fam Physician       Date:  2011-09       Impact factor: 3.275

3.  Relationship between statin use and colon cancer recurrence and survival: results from CALGB 89803.

Authors:  Kimmie Ng; Shuji Ogino; Jeffrey A Meyerhardt; Jennifer A Chan; Andrew T Chan; Donna Niedzwiecki; Donna Hollis; Leonard B Saltz; Robert J Mayer; Al B Benson; Paul L Schaefer; Renaud Whittom; Alexander Hantel; Richard M Goldberg; Monica M Bertagnolli; Alan P Venook; Charles S Fuchs
Journal:  J Natl Cancer Inst       Date:  2011-08-17       Impact factor: 13.506

4.  Statin induced myopathy presenting as mechanical musculoskeletal pain observed in two chiropractic patients.

Authors:  Robert J Rodine; Anthony C Tibbles; Peter Sy Kim; Neetan Alikhan
Journal:  J Can Chiropr Assoc       Date:  2010-03

5.  Predictors of cholesterol treatment discussions and statin prescribing for primary cardiovascular disease prevention in community health centers.

Authors:  Kunal N Karmali; Ji-Young Lee; Tiffany Brown; Stephen D Persell
Journal:  Prev Med       Date:  2016-04-16       Impact factor: 4.018

6.  Medication effectiveness may not be the major reason for accepting cardiovascular preventive medication: a population-based survey.

Authors:  Charlotte Gry Harmsen; Henrik Støvring; Dorte Ejg Jarbøl; Jørgen Nexøe; Dorte Gyrd-Hansen; Jesper Bo Nielsen; Adrian Edwards; Ivar Sønbø Kristiansen
Journal:  BMC Med Inform Decis Mak       Date:  2012-08-09       Impact factor: 2.796

7.  Decline in low-density lipoprotein cholesterol concentration: lipid-lowering drugs, diet, or physical activity? Evidence from the Whitehall II study.

Authors:  Kim Bouillon; Archana Singh-Manoux; Markus Jokela; Martin J Shipley; G David Batty; Eric J Brunner; Séverine Sabia; Adam G Tabák; Tasnime Akbaraly; Jane E Ferrie; Mika Kivimäki
Journal:  Heart       Date:  2011-04-12       Impact factor: 5.994

8.  Central versus peripheral cardiovascular risk in metabolic syndrome.

Authors:  H Edgell; R J Petrella; G J Hodges; J K Shoemaker
Journal:  Front Physiol       Date:  2012-02-27       Impact factor: 4.566

9.  Patterns and predictors of statin prescription in patients with type 2 diabetes.

Authors:  Heiner K Berthold; Ioanna Gouni-Berthold; Michael Böhm; Wilhelm Krone; Kurt P Bestehorn
Journal:  Cardiovasc Diabetol       Date:  2009-05-13       Impact factor: 9.951

10.  Medication Underuse in Aging Outpatients with Cardiovascular Disease: Prevalence, Determinants, and Outcomes in a Prospective Cohort Study.

Authors:  Andreas D Meid; Renate Quinzler; Julia Freigofas; Kai-Uwe Saum; Ben Schöttker; Bernd Holleczek; Dirk Heider; Hans-Helmut König; Hermann Brenner; Walter E Haefeli
Journal:  PLoS One       Date:  2015-08-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.